Medera
PrivateLast Round
M&A
Feb 26, 2026
Est. Valuation
$100M
Total Funding Raised
$3.03M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Medera is a clinical-stage biopharmaceutical company that develops novel gene- and cell-based therapeutic candidates for cardiovascular, pulmonary, and vascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Medera Comparables
Compare Medera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Affinia Therapeutics | 86% | |
| XyloCor Therapeutics | 85% | |
| Nuevocor | 85% |
Medera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Feb 26, 2026 | ||||
| Reverse Merger | Sep 5, 2024 | ||||
| M&A | Nov 18, 2020 | ||||
| Grant | Jan 7, 2020 | ||||
| Grant | Jun 6, 2018 | ||||
Grant | Feb 26, 2018 |
Key People
Founding team and executive leadership
Medera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hong Kong Science and Technology Parks Corporation | Private Placement, VC Round |
| Innovation and Technology Commission | Grant |
| Keen Vision Acquisition Corporation | Reverse Merger, M&A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 135% MoM, reaching 4.2K.
- Feb 26, 2026
Raised $100M in an M&A round.
Recent news
Latest coverage and updates
- partners_withSep 22, 2026
Medera Inc. and National Heart Centre Singapore announced an expanded partnership in Singapore on Sep 22nd '26 to advance human mini-heart-based cardiac disease modeling, translational research, and next-generation non-animal drug discovery.
- expands_offices_inSep 22, 2026
Medera Inc. announced plans to establish a Singapore laboratory and office through an expanded partnership with the National Heart Centre Singapore to support cardiac disease modeling, drug discovery, and regional cardiovascular research on Sep 22nd '26.
- attends_eventAug 31, 2026
Medera Inc. presents Late-Breaking 12-month MUSIC-HFpEF Phase 1/2a gene therapy trial data demonstrating durable improvement in cardiac filling pressures at ESC Congress 2026 in Germany on Aug 31st '26.
- attends_eventAug 31, 2026
Medera Inc. presents 12-month MUSIC-HFpEF Phase 1/2a trial data as a Late-Breaking Clinical Trial at the European Society of Cardiology Congress 2026 in Germany on Aug 31st '26.
- is_developingAug 24, 2026
As of Aug 24th '26, Medera Inc.'s Sardocor division is developing adeno-associated virus-based gene therapies for difficult-to-treat cardiovascular conditions, with IQVIA supporting the cardiac gene therapy clinical programs.
Medera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Medera's valuation, stock price, and market status.
Is Medera a public or private company?
Medera is a private company.
What is the current stock price of Medera?
Medera is a private company, so its shares have no public market price. Caplight tracks Medera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Medera worth (valuation)?
Medera's valuation is estimated at $100.0M based on funding round data.
Can I buy Medera stock?
Medera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Medera's last funding round?
Medera's most recent funding round was M&A on February 26, 2026.
Who are the main investors in Medera?
Key investors in Medera include Hong Kong Science and Technology Parks Corporation, Innovation and Technology Commission, Keen Vision Acquisition Corporation.
Will Medera IPO soon?
No public IPO plans have been announced for Medera.
How can I track Medera secondary market activity?
Caplight tracks bids, offers, and trades in Medera's shares on secondary markets.